VVY Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. The company was founded in 1997 and is based in Halle, Germany.…
Industry Peers
BiotechnologyKey Statistics
About Vivoryon Therapeutics (AMS: VVY)
›
Vivoryon Therapeutics (AMS: VVY) is listed on Euronext Amsterdam, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 13 employees.
The shares were at 0.6400 EUR on 19 November 2026, down 60.6% over 52 weeks. Its 52-week range is 0.5340 EUR to 1.648 EUR: the price is 61.2% below the high and 19.9% above the low.
Its market capitalisation is 18.95M EUR.
Vivoryon Therapeutics reports return on equity of -187.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 2.37M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 22 April 2027.